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Alzheimer's disease is connected to a number of other neurodegenerative conditions, known collectively as ‘tauopathies’, by the presence of aggregated tau protein in
the brain. Neuroinﬂammation and oxidative stress in AD are associated with tau pathology and both the breakdown of axonal sheaths in white matter tracts and excess
iron accumulation grey matter brain regions. Despite the identiﬁcation of myelin and iron concentration as major sources of contrast in quantitative susceptibility
maps of the brain, the sensitivity of this technique to tau pathology has yet to be explored. In this study, we perform Quantitative Susceptibility Mapping (QSM) and
T2* mapping in the rTg4510, a mouse model of tauopathy, both in vivo and ex vivo. Signiﬁcant correlations were observed between histological measures of myelin
content and both mean regional magnetic susceptibility and T2* values. These results suggest that magnetic susceptibility is sensitive to tissue myelin concentrations
across different regions of the brain. Differences in magnetic susceptibility were detected in the corpus callosum, striatum, hippocampus and thalamus of the rTg4510
mice relative to wild type controls. The concentration of neuroﬁbrillary tangles was found to be low to intermediate in these brain regions indicating that QSM may be
a useful biomarker for early stage detection of tau pathology in neurodegenerative diseases.1. Introduction
Alzheimer's disease (AD) is deﬁned by the presence of amyloid-β
plaque and neuroﬁbrillary tangle (NFT) tau pathology found primarily in
grey matter regions of the brain. These insoluble plaques and tangles
have both been found to contain iron (Lovell et al., 1998; Good et al.,
1992). Iron levels need to be tightly regulated in the brain but homeo-
stasis can become disturbed during neuroinﬂammation which is thought
to increase iron levels in neurons and microglia (Urrutia et al., 2013).
Oxidative stress is associated with the dysfunction of oligodendrocytes in
AD (Cai and Xiao, 2015) and white matter degradation has been detected
by histopathological examination in over 50% of patients (Sj€obeck et al.,
2005). Numerous white matter changes in AD have been reported in post
mortem studies including decreased myelin density (Sj€obeck et al.,
2005), decreased myelin basic protein (Wang et al., 2004), loss of oli-
godendrocytes (Sj€obeck et al., 2006), activation of microglia (Gouw
et al., 2008), as well as denudation of the ventricular ependyma, gliosis
and the loss of myelinated axons (Scheltens et al., 1995). In-vivo* Corresponding author.
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concentration of iron and myelin in brain tissue, may play a key role in
tracking the progressive pathology of AD and provide a means by which
to measure the efﬁcacy of therapeutics.
Quantitative Susceptibility Mapping (QSM) (Wang and Liu, 2015;
Shmueli et al., 2009; Haacke et al., 2015; Liu et al., 2014; Deistung et al.,
2016), uses the phase of the MRI signal to calculate maps of the bulk
magnetic susceptibility of tissue. Myelin is diamagnetic and has been
shown to be a predominant source of susceptibility contrast between
white and grey matter (Liu et al., 2011a; Klohs et al., 2013; Lee et al.,
2012). Furthermore, magnetic susceptibility measurements in white
matter regions using QSM have been shown to be more speciﬁcally
related to myelin concentration than measures of diffusion using DTI
(Argyridis et al., 2014). In addition to its dependence on myelin, mag-
netic susceptibility has been shown to correlate with iron concentrations
in tissue (Langkammer et al., 2012; Bilgic et al., 2012), and, like ﬁndings
of reduced T2*in AD (Moon et al., 2012; Zhao et al., 2017), these in-
creases have been attributed to increased iron deposition.r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Imaging pulse sequences and parameters. For in-vivo acquisition, a ﬂow compensated 3D
GRE sequence was used to generate data for QSM and a Multi-Echo 3D GRE sequence for
T2* mapping data. A Multi-Echo 3D GRE acquisition was used to collect ex-vivo QSM and
T2* mapping data. Abbreviations: NE: Number of echoes, NSA: Number of signal averages.
Parameter \
Pulse seq.
In-vivo (QSM): Flow
compensated 3D GRE
In-vivo (T2*): 3D
multi-echo GRE
Ex-vivo (QSM/T2*):
3D multi-echo GRE
TR (ms) 250 250 200
minTE/
ΔTE/
maxTE
(ms)
15 2.31/2.46/29.32 3.05/3.92/46.21
FA (0) 32 32 36
NE 1 12 12
NSA 1 1 5
Scan time 1hr,2s 1hr,2s 10hr,45min,2s
Spectral
width (Hz)
50000 100000 73529
FOV (mm) 18  18  18 18  18  18 18  17.2  14.4
Matrix 120  120  120 120  120  120 225  215  180
Resolution
(μm)
150  150  150 150  150  150 80  80  80
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bility were detected in AD patients relative to controls in the putamen, a
sub region of the striatum (Acosta-Cabronero et al., 2013). In the ArcAβ,
an amyloidmouse model of AD, smaller susceptibility increases over time
were observed relative to controls in a longitudinal study using a linear
mixed effects modelling analysis that incorporated estimates from mul-
tiple brain regions (Klohs et al., 2013). Thus far, no susceptibility map-
ping studies have been performed in mice exhibiting tau pathology
associated with AD.
The rTg4510 mouse model of tauopathy contains the P301L human
tau mutation, and accumulates NFTs in a progressive manner along with
motor and behavioural deﬁcits that are similar to those in human AD
(Lewis et al., 2000). Previous work in this model has identiﬁed abnor-
malities in the white matter of the corpus callosum using DTI and Elec-
tron Microscopy (Wells et al., 2015; Sahara et al., 2014). Additionally,
reactive microglia and astrocytes, associated with neuroinﬂammation
and iron accumulation, are known to be present in higher quantities in
the rTg4510 than in controls (Maphis et al., 2015; Yoshiyama et al.,
2007). We hypothesized that QSM might provide a sensitive in-vivo
method to non-invasively probe these pathological traits of the rTg4510
mouse model.
In this study, we present in-vivo QSM and T2* maps in the rTg4510
mouse, supported by higher resolution measurements from ex-vivo
datasets. A semi-automatic segmentation of the quantitative parameter
maps was employed to calculate magnetic susceptibility and T2*values in
selected grey matter and white matter regions. The biological factors
contributing to magnetic susceptibility and T2* measurements in the
tissue were investigated by comparison with histological stains for
myelin, iron, and neuroinﬂammatory markers to aid interpretation of the
MRI ﬁndings.
2. Materials and methods
2.1. Animals
Female rTg4510 transgenic mice were licensed from the Mayo Clinic
(Jacksonville Florida, USA) and bred for Eli Lilly by Taconic (German-
town, USA) (Ramsden et al., 2005a). Mice were imported to the UK for
imaging studies at the Centre for Advanced Biomedical Imaging, Uni-
versity College London. All studies were carried out in accordance with
the United Kingdom Animals (Scientiﬁc Procedures) act of 1986.
2.2. In-vivo data acquisition
In-vivo imaging was conducted on rTg4510 mice (n ¼ 10) and wild-
type (WT) controls (n ¼ 10) aged 7.5 months. Data were acquired with
a 9.4 T VNMRS horizontal bore scanner (Agilent Inc.). A 72 mm inner
diameter volume coil (Rapid Biomedical) was used for RF transmission
and signal was received using a two-channel head array (Rapid
Biomedical). Mice were anaesthetised under 2% isoﬂurane in 100% O2
and were immobilised by securing the head with a bite bar and ear bars.
The anaesthesia was subsequently reduced to 1.5% isoﬂurane and
maintained at this level throughout imaging. Core temperature and
respiration were monitored using a rectal probe and pressure pad (SA
instruments). Mice were maintained at ~37 C using heated water tubing
and a warm air blower with a feedback system (SA instruments). Shim-
ming was performed using an automatic 3D gradient echo shim function
(VNMRJ, Agilent Inc.) in a voxel (1 cm3) centred in the cortex resulting in
linewidths of 47 ± 7 Hz. Data for QSM was collected using a 3D single
echo spoiled gradient recalled echo (GRE) sequence with ﬁrst order ﬂow
compensation applied in three dimensions. Subsequently, a multi-echo
sequence was run without ﬂow compensation to acquire data for T2*
mapping. Parameters for MRI pulse sequences are provided in Table 1.
Flow compensation can improve phase estimation in vivo by reducing
errors caused by mislocalisation of signal and accumulation of spins due
to motion at a constant velocity (Haacke et al., 2015; Xu et al., 2014;335Deistung et al., 2009). Consequently, the multi-echo data, which were
not ﬂow compensated, were not used for QSM.
2.3. Preparation of ex-vivo samples
Animals were terminally anaesthetised with Euthanal administered
via intraperitoneal injection immediately after in-vivo imaging. Fixation
was then carried out by perfusion through the left ventricle: ﬁrst with
15–20 mL of saline (0.9%) and heparin; second with 50 mL of buffered
formal saline (10% solution, Sigma-Aldrich), at a ﬂow rate of 3 mL per
minute. Brains (in-skull) were then removed and stored at 4 C in buff-
ered formal saline. After 4 weeks, brains were transferred to phosphate
buffered saline (50 ml PBS refreshed weekly, Sigma-Aldrich) for rehy-
dration (Zhang et al., 2012; Shepherd et al., 2009; Benveniste and
Blackband, 2002) for a further 3 weeks.
2.4. Ex-vivo data acquisition
Ex-vivo imaging was conducted on rTg4510 mice (n ¼ 8) and wild-
type controls (n ¼ 8) using a 3D spoiled GRE acquisition with parame-
ters given in Table 1. Four mice from the in-vivo cohort were excluded
from ex-vivo processing due to non-optimal perfuse ﬁxation. Each brain
(in-skull) was secured individually in a 20 ml syringe ﬁlled with 10 ml
proton MR signal-free, non-viscous Fomblin perﬂuoropolyether (PFS-1,
Solvay Solexis SpA., Bollate, Italy) prior to imaging in a 26 mm diameter
birdcage coil (Rapid Biomedical GmbH, Germany) at 9.4T. Shimming
was conducted manually using a pulse-acquire sequence giving a line-
width of 47 ± 5 Hz.
Following ex-vivo imaging, the brains were then transferred to buff-
ered formal saline before being dispatched for histology.
2.5. Quantitative Susceptibility Mapping and T2* mapping
The reconstruction of the in-vivo phase data required a pre-processing
step to combine the signal from the two receive coils using a global offset
correction technique to remove phase shifts between channels (Ham-
mond et al., 2008). In-vivo phase data were unwrapped using Laplacian
unwrapping (unwrapLaplacian.m, MEDI toolbox, Cornell MRI Research
Lab, http://weill.cornell.edu/mri/pages/qsm.html (Liu et al., 2011b))
before background ﬁeld removal using a Variable Sophisticated Har-
monic Artifact Reduction for Phase data (VSHARP) (Schweser et al.,
2011; Wu et al., 2012) (minimum kernel width ¼ 3 voxels). Thresholded
k-space division (TKD) (Shmueli et al., 2009) (threshold t ¼ 5) was then
performed on the ﬁeld map to calculate magnetic susceptibility maps.
Ex-vivo QSMs were generated by path-based unwrapping
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phase data followed by VSHARP background ﬁeld removal (minimum
kernel width¼ 7 voxels) and TKD (threshold t¼ 5). QSM using all twelve
echoes was attempted by unwrapping the ex-vivo phase data temporally
and generating ﬁeld maps using a linear least squares ﬁt at each voxel.
However, maps of the R2 value from the ﬁtting indicated multiple regions
of poor ﬁt which manifested as increased noise and artifacts in the sus-
ceptibility maps which were consequently not used for analysis.
Masks used with the VSHARP algorithm were generated automati-
cally as described in the following section. The TKD threshold of t ¼ 5
was chosen to maximise contrast to noise ratio between white matter and
grey matter (GM) regions (determined during optimisation of the post
processing pipeline).
T2* estimates were calculated for each voxel by ﬁtting a mono-
exponential signal decay function across all echoes in Matlab.
2.6. Registration and mask generation
Regional estimates of magnetic susceptibility and T2* were con-
ducted using a semi-automatic segmentation of the quantitative maps.
This required co-registration of the corresponding magnitude images
(mean magnitude taken across all echoes for each subject) using an
automated software pipeline (Powell, 2017) that incorporated the
following steps. Automatic orientation of the brain images by rigid
registration to a standard atlas was followed by an intensity
non-uniformity correction (N4ITK algorithm) before automatic skull
stripping using the STEPS algorithm (Tustison et al., 2010) which also
generated masks for each brain. Group-wise registration of echo magni-
tude images was then performed using NiftyReg software (Modat et al.,
2010; Ourselin et al., 2001). First, all subjects were rigidly aligned to a
randomly chosen target member of the group. This was followed by 10
iterations of afﬁne registration, producing a matrix describing the global
transformations for each brain. There were then 20 iterations of non-rigid
registration (NRR). After each iteration, the intensity average image was
found from all registered, resampled magnitude images, and used as the
target for the subsequent registration. Deformation ﬁelds describing the
transformation resulting from this non-rigid registration were generated
for each brain. These deformation ﬁelds were applied to the QSMs and
T2* maps of the individual mice to transform them into a common image
space. Mean maps of the registered data were then calculated separately
for the WT (in-vivo: n ¼ 10, ex-vivo: n ¼ 8) and rTg4510(in-vivo: n ¼ 10,
ex-vivo: n ¼ 8) groups.
The QSM methodology described here produces magneticFig. 1. ROIs were drawn in rostral and caudal sections (0.5 mm thickness) in the atlas of the ma
Striatum (Str) and Anterior Commissure (AC). In the Caudal section (c), regions were drawn in t
336susceptibility measures that are relative rather than absolute (Cheng
et al., 2009; Straub et al., 2016). Prior to group comparisons, values at
each voxel were recalculated relative to an internal reference region. As
reported previously (Argyridis et al., 2014), we used the mean magnetic
susceptibility of the whole brain as an internal reference. This was
calculated using the brain masks produced by the STEPS algorithm.
Selected regions of interested (ROIs) were drawn manually using the
mean coregistered average image (Fig. 1) and were propagated back to
the quantitative susceptibility and T2* maps, using the deformations
from group-wise registration. Mean estimates of quantitative MRI mea-
sures were generated by delineation of ROIs in the atlas magnitude im-
ages before transformation back into the original image space of each
animal where maps were segmented. Slight errors in segmentation
propagation, assessed visually, were corrected manually in a small
number of regions. ROIs were selected to include WM and GM regions
known to be affected by tau pathology at this age (Wells et al., 2015;
Sahara et al., 2014). Mean values were calculated in each ROI for com-
parisons between the rTg4510 and WT groups.
2.7. Histology
Brain samples were processed using the Tissue TEK VIP processor
(GMI Inc, Ramsey, MN, USA) before being embedded in parafﬁn wax for
coronal brain sectioning (6 μm). Immunohistochemistry (IHC) was per-
formed as previously described (Wells et al., 2015) with antibodies
speciﬁc for myelin basic protein (MBP, 1:7000; Ab40390, Abcam),
phosphorylated tau (PG-5, 1:8000), astrocytes (GFAP, 1:3000; PU020,
Biogenex) and microglia (Iba-1, 1:6000; Wako). PG-5 and MBP staining
was performed in rTg4510 mice (n ¼ 5) and WT controls (n ¼ 5) at two
coronal levels corresponding to the rostral and caudal slices in the MR
data (determined manually using the Bregma as an anatomical refer-
ence). PG-5, GFAP, Iba-1, and Perls’ Prussian blue (PPB) IHC was carried
out in a single selected mouse from each group. IBA-1 and GFAP IHC
were performed to identify reactive microglia and astrocytes that are
thought to mediate neuroinﬂammation (Urrutia et al., 2013).
Regions of positive PG-5 and MBP staining caused reduced intensity
in the digital images of the histology slices. ROIs were segmented
manually (ImageJ) in these images and measures of NFT and myelin
content in the selected ROIs were produced by subtracting the mean
intensity in these regions from the maximum possible greyscale intensity
(255) to calculate the intensity reduction caused by PG-5 and MBP
staining. It was intended that Tau IHC be used to identify a ‘pathology-
free’ control region in rTg4510 tissue that would be used to normalisegnitude images(a). In the rostral section(b), ROIs were drawn in the corpus callosum (CCr),
he Cortex (Ctx), the corpus callosum (CCc), the Hippocampus (Hp), and the Thalamus (Th).
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the staining method. However, a pathology free area was not evident in
the rTg4510 Tau IHC (Fig. 2b) and consequently a content measure in an
ROI drawn over the whole brain tissue region in the image was used for
normalisation of the NFT and Myelin measures.
To investigate white matter atrophy, the thickness of the rostral and
caudal corpus callosum and anterior commissure were measured. A pixel
measurement was taken in the MBP histology images (ImageJ) at a
central point in the white matter structure (example location for rostral
corpus callosum shown by yellow arrows Fig. 7 a, b).
2.8. Statistics
All statistical analysis was performed using Graphpad Prism software
(Version 6.01) (Motulsky, 1999). To investigate the relationship between
in-vivo magnetic susceptibility and T2* estimates with corresponding
measurements in high resolution ex-vivo data, intra regional comparisons
were carried out in the wild-type group using individual t-tests (false
discovery rate corrected for multiple comparisons (q  0.05)). To eval-
uate inter regional differences in susceptibility, T2*, NFT and MBP in-
tensity, one-way ANOVA comparisons were carried out. The relationship
between the regional myelin content and corresponding susceptibility
and T2* values in all regions was investigated using Pearson correlations.
Finally, to investigate differences between the rTg4510 and WT groups,
the mean regional susceptibility, T2* and myelin content were compared
between rTg4510 and WT groups with p-values reported from standard
two tailed t-tests.
3. Results
3.1. Regional measurements of NFT content
There was very little PG-5 staining visually apparent in the WT mice
compared to the dense and widespread staining in the rTg4510 mice
(Fig. 2 a, b). Within the rTg4510 group, all regional measures were
signiﬁcantly different in the grey matter regions (Fig. 2c) (p < 0.05) with
the exception of the Hippocampus and Cortex. In agreement with pre-
vious studies at this time point (Wells et al., 2015; Holmes et al., 2016),Fig. 2. PG-5 staining of NFTs in rostral slice of representative WT(a) and rTg4510(b) mice. NFT
matter regions(d) (mean and standard deviation).
337the NFT content was lowest in the thalamus and highest in the cortex
with intermediate levels in the striatum and hippocampus.
In white matter regions of the rTg4510, NFT content levels were
similar to intermediate levels measured in the grey matter. The NFT
content in the rostral corpus callosumwas found to be signiﬁcantly lower
than that of the caudal corpus callosum measurement (p < 0.05).
The magnetic susceptibility and T2* measurements for all GM and
WM regions were plotted against NFT content estimates from histology in
the rTg4510 mice with no signiﬁcant correlations between parame-
ters observed.
3.2. Comparison of mean regional magnetic susceptibility and T2* between
WT and rTg4510 mice
An axial slice of mean QSM and T2*maps for each of the registered in-
vivo and ex-vivo datasets is shown in Fig. 3. The anatomical structures
were more clearly delineated in the ex-vivo data, owing in part to its ﬁner
resolution compared to the in-vivomaps. Enlargement of the ventricles in
the rTg4510 mice is evident in both the QSM and the T2* maps (Fig. 3:
Blue arrows in the rTg4510 T2* maps) and has been reported previously
(Wells et al., 2015; Holmes et al., 2016). Consistency between in-vivo and
ex-vivoWM-GM contrast is visually apparent in both QSM and T2* maps.
Relative to the surrounding grey matter, the white matter regions
appeared hypointense indicating a more diamagnetic (negative) sus-
ceptibility and shorter T2*. In-vivo and ex-vivomeasurements of magnetic
susceptibility and T2* in rTg5410 and WT mice are presented in Table 2.
Differences in magnetic susceptibility were detected both in vivo and ex
vivo in the striatum, hippocampus, thalamus, and rostral corpus callosum.
In contrast to these regions of low and intermediate NFT content, there
were no differences in magnetic susceptibility detected in the cortex, the
region of highest NFT burden.
In grey matter regions, differences in magnetic susceptibility and T2*
were most signiﬁcant in the striatum of the rTg4510. In both the in-vivo,
and ex-vivo datasets, the rTg4510 group had increased paramagnetic
susceptibility(p < 0.01) (Table 2) and a reduced T2* (p < 0.001) in the
striatum relative to WT controls. This region appears brighter in the ex-
vivo mean susceptibility maps (yellow circle, Fig. 4 a, b) in the rTg4510.
In the hippocampus, the rTg4510 mice had a signiﬁcantly greater meancontent measurements in PG-5 histology are provided in grey matter regions (c) and white
Fig. 3. Mean QSM (a–d) and T2*(e–h) images for registered ex-vivo (a, b, e, f) and in-vivo (c, d, g, h) datasets. A reduction in the grey/white matter contrast can be seen in a rostral section
of the corpus callosum in the rTg4510 QSMs that is not apparent in the T2* maps (yellow arrows). Enlarged ventricles are evident in the rTg4510 maps (blue arrows).
Table 2
List of mean and standard deviation of regional measures of magnetic susceptibility and T2*. Abbreviations for white matter regions: CCr – rostral corpus callosum, AC - anterior commissure,
CCc caudal corpus callosum. Symbols used in plots: *p < 0.05 **p < 0.01, ***p < 0.001, ****p < 0.0001 denote statistical differences between WT and rTg4510 regional measurements;
yp < 0.05 yyp < 0.01, yyyp < 0.001, yyyyp < 0.0001 denote statistical differences in WT regional measurements between in-vivo and ex-vivo data.
ROI Ex vivo In vivo
WT rTg4510 WT rTg4510
χ (ppb)
Striatum 0.61 ± 0.81 8.71 ± 3.21*** 0.54 ± 1.31 4.85 ± 3.09**
Hippocampus 9.45 ± 2.55yy 13.60 ± 2.91** 5.82 ± 1.86 11.11 ± 4.84**
Cortex 7.01 ± 0.92yy 2.72 ± 5.37 3.46 ± 3.06 1.40 ± 1.79
Thalamus 1.30 ± 0.97 3.03 ± 1.31** 1.33 ± 1.09 0.45 ± 1.2**
CCr 34.92 ± 4.29yyyy 18.73 ± 7.6*** 20.55 ± 6.15 11.22 ± 5.21**
AC 32.32 ± 1.88yyyy 31.58 ± 3.33 13.33 ± 3.45 9.42 ± 5.34
CCc 46.01 ± 3.97yyyy 48.70 ± 8.88 18.31 ± 10.14 17.10 ± 4.43
T2* (ms)
Striatum 39.79 ± 1.14yyyy 35.08 ± 1.61**** 34.99 ± 1.82 31.58 ± 1.42***
Hippocampus 50.16 ± 1.51yyyy 50.39 ± 2.39 36.89 ± 2.48 36.62 ± 2.55
Cortex 46.14 ± 1.44yyyy 45.13 ± 1.81 33.67 ± 1.4 32.01 ± 1.8*
Thalamus 37.41 ± 1.1yyyy 35.57 ± 1** 31.25 ± 2.44 31.72 ± 0.59
CCr 25.23 ± 0.86yyyy 26.67 ± 2.1 22.58 ± 0.82 24.20 ± 3.2
AC 24.60 ± 0.73 22.89 ± 0.81*** 26.46 ± 2.35 25.27 ± 2.08
CCc 24.08 ± 1.07 23.54 ± 1.25 25.02 ± 1.54 24.73 ± 1.72
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vivo (p < 0.01), with no signiﬁcant differences in T2* (Table 2). In the
cortex, a signiﬁcant shortening of T2* in the rTg4510s was observed in
vivo only (p < 0.05). The mean susceptibility ex vivo was signiﬁcantly
elevated in the rTg4510 thalamus which also had a signiﬁcantly reduced
T2*(p < 0.01), ﬁndings that were not replicated in vivo where magnetic
susceptibility was found to be signiﬁcantly decreased (p < 0.01) with no
signiﬁcant change in T2*.
In addition to the susceptibility differences in the rostral corpus cal-
losum of the rTg4510 mice, an ex-vivo reduction in T2* (p < 0.001) was
observed in the anterior commissure white matter region. In the caudal
corpus callosum, the WM region exhibiting the highest NFT content, no
differences in MRI measurements were detected in the rTg4510 mice.338Focusing on the WT data (Table 2), we observed regional differences
in the magnetic susceptibility and T2* between the in-vivo and ex-vivo
data, presumably due to ex-vivo tissue processing. Broadly, magnetic
susceptibility and T2* increased in ex-vivo GM tissue regions (Table 2,
p  0.01) (with the exception of susceptibility in the Thalamus and
Striatum). In WM regions, magnetic susceptibility was decreased in the
ex-vivo tissue (Table 2, p  0.0001) with no differences observed in T2*
(with the exception of the rostral corpus callosum).
3.3. Regional measurements of myelin and iron content
Differences in myelin content between the rTg4510 and WT mice
were evaluated through comparison of the regional estimates from the
Fig. 4. Increased magnetic susceptibility in the striatum of the rTg4510 (relative to WT) was observed visually in group mean QSMs (a, b (yellow circles)).
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ence with myelin content increased in the rTg4510 group relative to the
WT group (p < 0.01) (Fig. 5a). A reduction in the thickness of white
matter structures was visually apparent in the rTg4510 compared to WT
mice. Measurements of tract thickness were taken in the MBP histology
images (Fig. 5b) and a signiﬁcant reduction in was identiﬁed in all white
matter structures (p < 0.05). The decrease was most signiﬁcant in the
caudal corpus callosum (P < 0.001). The percentage decrease in the mean
thickness of WM structures in the rTg4510 mice relative to the WTs were
calculated as 39% for the caudal corpus callosum, 25% for the rostral
corpus callosum, and 25% for the anterior commissure.
There were no visually apparent regions of positive PPB staining
evident in the selected WT and rTg4510 mice (Supplementary Fig. S1).3.4. Correlation of myelin content measurements with MRI parameters
The magnetic susceptibility and T2* measurements for all GM andFig. 5. Myelin content (a) and white matter structure thickness measurements(b) in WT
and rTg4510 mice (n ¼ 5). White matter thickness was measured by number of pixels in
the histology images. Symbols used in plots: *p < 0.05 **p < 0.01, ***p < 0.001.
339WM regions were plotted against myelin content estimates from MBP
histology. Signiﬁcant correlations were identiﬁed between myelin con-
tent measurements and magnetic susceptibility (p < 0.0001, for in-vivo
and ex-vivo data) and T2* (p < 0.0001, for in-vivo and ex-vivo data) when
animals from both rTg4510 and WT cohorts (n ¼ 5 for each) were
included in the analysis (Fig. 6). Signiﬁcant correlations were also
observed between these variables when analysing WT and rTg4510
groups separately (p < 0.0001). These correlations indicated a relation-
ship between increasing myelin content and decreasing magnetic sus-
ceptibility and T2* in the brain regions sampled.3.5. Markers of neuroinﬂammation in regions of intermediate and low NFT
deposition
In the genu of the corpus callosum, ﬁndings of increased magnetic
susceptibility were accompanied by a disorganised arrangement of
myelin in the rTg4510, with rarefaction and vacuolisation evident in
MBP staining (Fig. 7c and d). An increased density of staining for reactive
microglia (Fig. 7e and f) and astrocytes (Fig. 7g and h) was also observed
in the rTg4510 relative to WT controls. Increased GFAP and IBA-1
staining were also visually apparent in other regions of intermediate
and high NFT content (not shown).
In the Thalamus, a region of low NFT deposition, increased levels of
IBA-1 (Fig. 8c and d) and GFAP (Fig. 8e and f) staining were visually
apparent in a region of minimal NFT staining (Fig. 8b).
4. Discussion
In this study we have used semi-automated segmentation techniques
to provide a comparison of magnetic susceptibility and T2* measures in
selected regions in the rTg4510 mouse model of tauopathy with values in
WT controls. This mouse model accumulates NFTs throughout the fore-
brain progressively with age in a manner similar to the accumulation
observed in the human form of AD. To support in-vivoQSM ﬁndings, high
resolution imaging and myelin sensitive staining were performed on ex-
vivo tissue samples from the same cohort of mice. Differences in magnetic
susceptibility were observed in regions of low and intermediate NFT
burden along with an increased presence of markers of neuro-
inﬂammation. Correlations between MRI and MBP measures indicate
that myelin may be a key driver of regional susceptibility and T2* values.
These ﬁndings suggest that tissue magnetic susceptibility provided by
QSM may be useful as a non-invasive marker of tau pathology in its
early stages.4.1. Ex-vivo vs. in-vivo comparisons in WT mice
Unlike clinical applications of the QSM technique, animal imaging
offers the additional possibility of comparing susceptibility values in
vivo with those acquired subsequently in the same group of subjects ex
Fig. 6. Regional myelin content (MBP intensity reduction) vs in-vivo (a, b) and ex-vivo (c, d) magnetic susceptibility (a, c) and T2*(b, d) measurements in all brain regions (n ¼ 7) for both
WT(n ¼ 5) and rTg4510 (n ¼ 5) mice. Pearson's coefﬁcient r (given to two decimal places) and p values for correlations are provided. The best-ﬁt line is shown with dotted lines indicating
the 95% conﬁdence band.
J. O'Callaghan et al. NeuroImage 159 (2017) 334–345vivo. Relative to ex-vivo acquisition, additional error may be intro-
duced into in-vivo datasets from increased noise and motion artifacts,
primarily of physiological origin that ﬂuctuate with the cardiorespi-
ratory cycle (Jack et al., 2005; Oguz et al., 2013). Errors may also arise
from partial volume effects due to the lower resolution attainable in
vivo. Furthermore, the use of 100% O2 to deliver anaesthetic may alter
levels of deoxyhemoglobin in the blood, thereby affecting the physi-
ological accuracy of susceptibility estimates. This might suggest that a
fairer group comparison can be achieved using ex-vivo data. However,
tissue ﬁxation processes and the reduction in imaging temperature will
alter relaxation properties (Shepherd et al., 2009; Rieke and Pauly,
2008) and susceptibility values (Quesson et al., 2000; Poorter et al.,
1995) so that measurements may not reﬂect true values in vivo. To
evaluate the effects of these differences, QSM and T2* data were
collected both in vivo and ex vivo in the same cohort of mice. Signiﬁ-
cant increases in both measures were observed ex vivo in grey matter
regions in the wild-type mice (Table 2). In the case of T2*, this may
have been caused by the ﬁxation and rehydration processes, known to
lengthen the T2 (and therefore T2*) properties of the ex-vivo tissue
(Shepherd et al., 2009) relative to in-vivo tissue. Increases in ex-vivo
susceptibility measurements in the grey matter regions may be due to
the known inverse relationship between magnetic susceptibility and
temperature of paramagnetic materials, which has been used to adjust
ex-vivo susceptibility values previously (Langkammer et al., 2012).
White matter regions displayed an increased negative susceptibility ex
vivo than measured in vivo. This ﬁnding is supported by a previous
study in the optic nerve in rats (Luo et al., 2014) but may also be due
to partial volume errors in the in-vivo analysis. The in-vivo voxel size
used (150 μm isotropic) was large relative to the white matter struc-
tures in the mouse brain and incorporation of grey matter into ROIs
may have increased the mean and standard deviation of susceptibility
measurements relative to the ex-vivo data, which employed smaller340voxels (80 μm isotropic).
4.2. Susceptibility and T2* differences between regions within mice
Differences in magnetic susceptibility estimates between grey and
white matter regions were in good agreement with previously published
values for in-vivo (Klohs et al., 2011, 2013) and ex-vivo (Liu et al., 2011a)
wild-type mice. Both in-vivo and ex-vivo datasets displayed a pattern of
lower values of magnetic susceptibility and T2* in the striatum and
thalamus relative to the grey matter regions in the cortex and hippo-
campus. These reduced values may be due to the greater myelin content
measured in the striatum and thalamus. Myelin is diamagnetic and pro-
duces a shortening of T2* and reduces the bulk magnetic susceptibility of
tissue (Liu et al., 2011a; Klohs et al., 2013; Lee et al., 2012; Dibb et al.,
2014). The possibility that myelin plays a key role in the MRI measures in
the WT cohort is supported by the correlations between regional sus-
ceptibility, T2*, and myelin content measurements. A relationship be-
tween decreasing magnetic susceptibility and T2*with increasing myelin
content was demonstrated in the in-vivo and ex-vivo data for both the WT
and rTg4510 groups. These results appear to show that myelin concen-
tration in the brain is a major contributor to magnetic susceptibility and
T2* measured using MRI and that increasing myelin levels reduce both
the magnetic susceptibility and T2* values (Stüber et al., 2014).
4.3. Group comparisons between rTg4510 and WT mice
In comparisons of regional susceptibility estimates between the WT
and rTg4510 groups, the rTg4510s exhibited differences both in vivo and
ex vivo in the striatum, hippocampus, thalamus and rostral corpus cal-
losum. NFT content measurements indicate that these are regions of low
and intermediate tau pathology. Regions of highest NFT content mea-
sures in the grey matter(cortex) and white matter (caudal corpus
Fig. 7. QSMs and histology in the rostral section of the corpus callosum in representative mice(a-h). A reduction in grey matter/white matter contrast was apparent in rTg4510 ex vivo
QSMs (a, b). Staining in the genu section of the corpus callosum (yellow arrows) showed rarefaction and vacuolisation in myelin (c, d), and increased microglial (e, f) and astrocytic (g,
h) activity.
J. O'Callaghan et al. NeuroImage 159 (2017) 334–345callosum) (see Fig. 2) did not exhibit susceptibility differences which
may be due to the advanced stage of the pathology. Relative to other WM
regions, elevated NFT levels in the caudal corpus callosum were
accompanied by a larger and more signiﬁcant reduction in structural
thickness measured in the rTg4510 (Fig. 5b) which suggest a greater level
of neurodegeneration has occurred. In the cortex, the region of greatest
pathology in grey matter regions, severe atrophy at this time point has
been reported previously (Wells et al., 2015; Holmes et al., 2016).
Furthermore, NFT formation has been detected in the cortex at the
earliest stages of pathology in the rTg4510 (Ramsden et al., 2005b).
A decreased diamagnetism in the rostral corpus callosum was detec-
ted both in vivo and ex vivo in the rTg4510 (Table 2) and a loss of WM-GM
contrast was evident in the mean susceptibility maps (Fig. 3). Observa-
tions of vacuolisation and rarefaction in MBP staining in this region
(Fig. 7) were consistent with a previous study in which electron micro-
scopy observations identiﬁed myelin abnormalities from as early as 4
months in the rTg4510 mouse (Sahara et al., 2014). The increased GFAP
and IBA-1 staining in this region respectively indicate increased reactive
microglia and astrocytes associated with neuroinﬂammation. These
processes have previously been observed to occur as a result of demye-
lination in AD (Akiyama et al., 2000). However, there was no difference
in myelin content measurements relative to WT mice suggesting that at
this time-point, demyelination in the rTg4510 is not the root cause of
susceptibility changes.341With the exception of the hippocampus, no signiﬁcant differences
were detected in the regional mean myelin content measurements be-
tween the rTg4510 and WT groups. Greater levels were observed in the
hippocampus of the rTg4510 which may reﬂect increased myelin. Stress
has previously been implicated as a cause of increased hippocampal
myelin (Chetty et al., 2014). However, this ﬁnding is contrary to the QSM
results which showed an increase in hippocampal susceptibility in the
rTg4510s. It may be possible that the increased myelin content mea-
surement is a false positive, caused by a limitation in the staining mea-
surements protocol. In the slices selected, NFTs were prevalent
throughout the rTg4510 tissue so there was no obvious ‘pathology free’
region that could be used as a control to normalise for variability in PG-5
and MBP stains applied. Consequently, the mean of the stain intensity
across the whole brain region was used as a reference. While this should
be satisfactory for the intra-group correlation results, inherent
pathology-driven myelin differences in the whole brain reference in the
rTg4510 mice may introduce error into inter group comparisons. In both
the rostral and caudal slices, a slight decrease in the myelin content
measure in the whole brain reference region was observed in the
rTg4510 relative to the WT (this increase was not statistically
signiﬁcant).
Iron accumulation is another known cause of paramagnetic increases
in tissue in AD (Connor et al., 1992; Parsey and Krishnan, 1998) and has
previously been associated with tau pathology and inﬂammatory
Fig. 8. PG-5 staining in a region of low NFT deposition (a, b) in the thalamus (rTg4510), and IBA-1 (c, d) and GFAP (e, f) staining in the same region in a WT (c, e) and rTg4510 (d,
f) mouse.
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in the AD brain and can also give rise to increases in magnetic suscep-
tibility estimates and T2* shortening (Langkammer et al., 2012;
Acosta-Cabronero et al., 2013; Stüber et al., 2014). The results of PPB
staining for iron, a stain used previously to identify iron deposition in AD
mouse models (El Tannir El Tayara et al., 2006; Jack et al., 2004), were
negative in the rTg4510 mouse (Supplementary Fig. S1). However, DAB
intensiﬁcation of PPB IHC has been used in previous studies to provide
enhanced sensitivity to iron in the mouse brain (Lee et al., 2004; Wen-
genack et al., 2011) and could be applied to more conclusively exclude
the possibility of excess iron accumulation in the rTg4510.
In the thalamus, low levels of tau pathology were detected in the
rTg4510 mice, and has been observed previously that structural volume
loss does not occur at this time point (Wells et al., 2015). Neuro-
inﬂammatory processes are thought to precede and cause neuro-
degeneration in Alzheimer's Disease (Morales et al., 2014) and may
contribute to greater blood brain barrier permeability (Zenaro et al.,
2016). Reported increases in MR diffusion and perfusion measurements
support the possibility of blood barrier breakdown in the thalamus of the
rTg4510 (Wells et al., 2015). This would lead to an alteration in
composition of the interstitial space, altering levels of water and mac-
romolecules which will cause changes in the tissue bulk magnetic sus-
ceptibility (Quarantelli, 2015). With the progression of tau pathology,
neurodegeneration has been shown to occur in the rTg4510. This will
cause a loss of cells, axons, and myelin, and the tissue causing bulk
magnetic susceptibility to be altered in a manner that opposes early stage
changes (Zhao et al., 2016, 2017) and may explain the lack of differences
detected in regions of greatest NFT burden. The balance of competing
effects of tau pathology and neurodegenerative processes on bulk mag-
netic susceptibility will differ between brain regions in the rTg4510 mice
at the time point imaged, and may be responsible for the lack of an
observed correlation between QSM and NFT density parameters. Further
work would be required to unpick the biological alterations that occur
during neuroinﬂammatory and neurodegenerative processes and their342effects on tissue magnetic susceptibility.
The QSM and T2* techniques presented here can be acquired simul-
taneously using a single pulse sequence and the differing mechanisms
that drive their contrast suggest that they may offer complementary in-
formation (Shmueli et al., 2009; Deistung et al., 2013). There were a
small number of regions where group differences were identiﬁed in both
the susceptibility and T2* maps. An increased magnetic susceptibility
and decreased T2* was observed in the rTg4510 relative to wild-type
controls in vivo and ex vivo in the striatum and ex vivo only in the thal-
amus. In the rostral corpus callosum and hippocampus, in-vivo and ex-vivo
increases in magnetic susceptibility were observed in the rTg4510 in the
absence of T2* changes. This may reﬂect greater sensitivity of magnetic
susceptibility to changes in the rTg4510. Magnetic ﬁeld inhomogeneities
arising from background gradients can cause reductions in T2* estimates
and may introduce a bias into group comparisons. Maps of ﬁeld in-
homogeneity (ΔB0) were generated to investigate effects of these con-
tributions and no differences were identiﬁed between WT and rTg4510
datasets in vivo or ex vivo (Supplementary Fig. S2).
T2* displayed a correlation with myelin content measures that was of
greater statistical signiﬁcance than that for QSM. Possible sources of
increased variability in the susceptibility estimates may have arisen
through normalisation to a reference region and the vulnerability of this
QSM protocol to magnetic susceptibility anisotropy effects. Reference
regions are commonly used in QSM studies (Bilgic et al., 2012; Acosta-
Cabronero et al., 2013; Straub et al., 2016) and may introduce error
through a lack of consistency between subjects. However, it has been
found previously that effects of normalisation are minimal relative to
measureable differences in magnetic susceptibility (Acosta-Cabronero
et al., 2016). To reduce the effects of susceptibility anisotropy on mea-
surement comparisons, in-vivo and ex-vivo brains were positioned and
secured as consistently as possible betweenmice. However, there is likely
to be some variation in the orientation of brains relative to the B0 ﬁeld
and future work could use susceptibility tensor imaging (Liu, 2010) to
investigate these effects.
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single-echo ﬂow-compensated sequence that was used to acquire data for
QSM. The use of multi-echo data to generate ﬁeld maps using recently
developed phase unwrapping techniques such as CAMPUS (Feng et al.,
2013) or non-linear ﬁeld map estimation (Liu et al., 2013) may reduce
noise and improve magnetic susceptibility estimates (Emma Biondetti
and Shmueli, 2016). Further work to modify the multi-echo sequence to
include ﬁrst order gradient moment nulling for ﬂow compensation at
every echo time (Xu et al., 2014; Wu et al., 2016) would enable simul-
taneous in-vivo acquisition of data for both T2* and susceptibility map-
ping. However, it may not be necessary to use ﬂow-compensation at
9.4 T, especially when comparing regions which do not contain large
vessels. Further analysis including calculation of susceptibility maps from
the multi-echo T2* data acquired in vivo in this study and a comparison of
the resulting susceptibility values with the single-echo (Sun and Wilman,
2015; Biondetti et al., 2017) values would shed light on this. Scan time
could be further reduced using an Echo Planar readout for inclusion in an
in-vivo multi-parametric AD imaging protocol (Mesrob et al., 2012;
Walhovd et al., 2009; Cherubini et al., 2010; Yang et al., 2011; Lane
et al., 2017).
5. Conclusion
In this study, T2* mapping and QSM were conducted in a mouse
model of AD exhibiting tau pathology for the ﬁrst time. The results
indicate that both techniques are sensitive to regional differences in
myelin content in the mouse brain in vivo. Magnetic susceptibility dif-
ferences were observed in regions that exhibited low NFT burden and
increased staining for reactive microglia and astrocytes. QSM in the
rTg4510 may therefore constitute a novel in-vivo biomarker of neuro-
inﬂammation in the rTg4510 and a means by which to detect early tau
pathology and to test therapeutics. The QSM protocol implemented in
this work is analogous to clinical protocols that are currently available
and therefore could be simply incorporated into studies of human Alz-
heimer's Disease and other tauopathies.
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